BlossomHill Therapeutics, Inc.
BLSMBlossomHill Therapeutics, Inc. in brief
BlossomHill Therapeutics, Inc. is a listed company in the Biotechnology industry, based in San Diego, California, USA. Its market value was $458 M on 21 October 2026, which makes it the 12,964th largest listed company in the world and the 2,583rd largest in the USA on this site. Jingrong Jean Cui is its chief executive. Its shares trade under the symbol BLSM (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
BlossomHill Therapeutics, Inc. timeline
- 2021
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2026
- 🔔Initial public offering on NasdaqFinal prospectus filed with the SEC on 7 August 2026; shares registered for exchange trading on 4 August 2026.
Events of BlossomHill Therapeutics, Inc. from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #2,552 (Aug 2026) · #2,329 (Sep 2026) · #2,586 (Oct 2026)
Quarterly results
Latest quarter to Sep 2026: revenue —, net income $-24M.
SEC filings
- Nov 12, 202610-QQuarterly report · period to Sep 2026
- Nov 12, 20268-KCurrent reportResults of operations
- Sep 18, 202610-QQuarterly report · period to Jun 2026
- Sep 18, 20268-KCurrent reportResults of operations
- Sep 15, 20268-KCurrent reportRegulation FD disclosure
- Aug 10, 20268-KCurrent reportBylaws amended · Other events
- Aug 7, 2026424B4IPO prospectus
- Aug 3, 2026S-1/AIPO registration (amended)
- Jul 17, 2026S-1IPO registration
Official filings of BlossomHill Therapeutics, Inc. with the US Securities and Exchange Commission.
Balance sheet
- Total assets
- $163 M
- Total liabilities
- $38 M
- Total equity
- $-132 M
As of December-2025
Top 39 institutional investors in BlossomHill Therapeutics, Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Cormorant Asset Management, LP | 3,614,034 | New | 11.37% | $67 M | Nov 16, 2026 |
| 2 | Orbimed Advisors LLC | 2,714,279 | New | 8.54% | $51 M | Nov 16, 2026 |
| 3 | Perceptive Advisors LLC | 1,812,193 | New | 5.70% | $34 M | Nov 16, 2026 |
| 4 | Vivo Capital, LLC | 1,493,740 | New | 4.70% | $28 M | Nov 13, 2026 |
| 5 | Deerfield Management Company, L.P. | 1,446,000 | New | 4.55% | $27 M | Nov 16, 2026 |
| 6 | Jpmorgan Chase & Co | 1,415,331 | New | 4.45% | $26 M | Nov 12, 2026 |
| 7 | Janus Henderson Group Ltd. | 1,336,993 | — | 4.21% | $25 M | Nov 16, 2026 |
| 8 | FMR LLC | 1,027,293 | New | 3.23% | $19 M | Nov 10, 2026 |
| 9 | Vanguard Capital Management LLC | 433,302 | New | 1.36% | $8 M | Nov 13, 2026 |
| 10 | NEXTBio Capital Management LP | 250,000 | New | 0.79% | $5 M | Nov 13, 2026 |
| 11 | Silverarc Capital Management, LLC | 202,104 | New | 0.64% | $4 M | Nov 12, 2026 |
| 12 | Opaleye Management Inc. | 175,000 | New | 0.55% | $3 M | Nov 16, 2026 |
| 13 | BlackRock, Inc. | 147,686 | New | 0.46% | $3 M | Nov 13, 2026 |
| 14 | a16z Capital Management, L.L.C. | 125,000 | New | 0.39% | $2 M | Nov 16, 2026 |
| 15 | Geode Capital Management, LLC | 119,176 | New | 0.37% | $2 M | Nov 6, 2026 |
| 16 | Monashee Investment Management LLC | 80,000 | New | 0.25% | $1 M | Nov 6, 2026 |
| 17 | Ameriprise Financial Inc | 73,691 | New | 0.23% | $1 M | Nov 16, 2026 |
| 18 | Vanguard Fiduciary Trust Co | 60,281 | New | 0.19% | $1 M | Nov 13, 2026 |
| 19 | Citadel Advisors LLC | 55,000 | New | 0.17% | $1 M | Nov 16, 2026 |
| 20 | Birchview Capital, LP | 50,000 | New | 0.16% | $1 M | Nov 13, 2026 |
| 21 | Ghisallo Capital Management LLC | 50,000 | New | 0.16% | $1 M | Nov 16, 2026 |
| 22 | Millennium Management LLC | 45,818 | New | 0.14% | $1 M | Nov 16, 2026 |
| 23 | Goldman Sachs Group Inc | 30,805 | New | 0.10% | $1 M | Nov 16, 2026 |
| 24 | Walleye Capital LLC | 28,659 | New | 0.09% | $1 M | Nov 13, 2026 |
| 25 | Squarepoint Ops LLC | 23,150 | New | 0.07% | $0 M | Nov 9, 2026 |
Show all 39: investors 26 to 39
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | Northern Trust Corp | 21,337 | New | 0.07% | $0 M | Nov 16, 2026 |
| 27 | State Street Corp | 17,200 | New | 0.05% | $0 M | Nov 12, 2026 |
| 28 | D. E. Shaw & Co., Inc. | 12,034 | New | 0.04% | $0 M | Nov 16, 2026 |
| 29 | Vanguard Portfolio Management LLC | 10,932 | New | 0.03% | $0 M | Nov 13, 2026 |
| 30 | Jump Financial, LLC | 10,223 | New | 0.03% | $0 M | Nov 13, 2026 |
| 31 | Charles Schwab Investment Management Inc | 10,194 | New | 0.03% | $0 M | Nov 16, 2026 |
| 32 | Two Sigma Investments, LP | 10,100 | New | 0.03% | $0 M | Nov 16, 2026 |
| 33 | Aster Capital Management (DIFC) Ltd | 4,822 | New | 0.02% | $0 M | Nov 12, 2026 |
| 34 | Morgan Stanley | 4,677 | New | 0.01% | $0 M | Nov 13, 2026 |
| 35 | Vanguard Global Advisers, LLC | 3,765 | New | 0.01% | $0 M | Nov 13, 2026 |
| 36 | Legal & General Group Plc | 1,612 | New | 0.01% | $0 M | Nov 16, 2026 |
| 37 | Citigroup Inc | 1,279 | New | 0.00% | $0 M | Nov 4, 2026 |
| 38 | UBS Group AG | 997 | New | 0.00% | $0 M | Nov 10, 2026 |
| 39 | Osaic Holdings, Inc. | 512 | New | 0.00% | $0 M | Nov 12, 2026 |
Insider trading at BlossomHill Therapeutics, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | OrbiMed Capital GP VIII LLCDirector | Conversionindirect | +1.04 M | — | — | 1.04 M | Form 4 |
| filed | Carl L. GordonDirector | Conversionindirect | +1.04 M | — | — | 1.04 M | Form 4 |
| filed | OrbiMed Capital GP VIII LLCDirector | Conversionindirect | +1.05 M | — | — | 2.09 M | Form 4 |
| filed | Carl L. GordonDirector | Conversionindirect | +1.05 M | — | — | 2.09 M | Form 4 |
| filed | OrbiMed Capital GP VIII LLCDirector | Buyindirect | +625,000 | $16.00 | $10.0 M | 2.71 M | Form 4 |
| filed | Carl L. GordonDirector | Buyindirect | +625,000 | $16.00 | — | 2.71 M | Form 4 |
| filed | Yishan LiExecutive Chairman, Director, 10% owner | Conversionindirect | +1.60 M | — | — | 1.60 M | Form 4 |
| filed | Jason A. KeyesChief Financial Officer | Buy | +700 | $16.00 | $11 K | 700 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: BlossomHill Therapeutics, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
IPO: priced at $16.00, raising $150M · IPO calendar
Fails to deliver
- : 2,204 shares at $14.40
- : 1,026 shares at $21.34
- : 3,794 shares at $20.47
- : 4,322 shares at $22.34
- : 20,078 shares at $25.25
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
BlossomHill Therapeutics, Inc. scorecard#
Passes 1 of the 2 checks that could be worked out. Fiscal year 2025; market cap of Oct 21, 2026.
Valuation0 of 1
- –P/E below its peers' medianNo P/E on file.
- ✗Price to book below its peers' medianNo price to bookShareholders' equity is negative.
- –Price to sales below its peers' medianNo Price to sales on file.
- –Free cash flow yield above 5%No free cash flow yield on file.
- –Earnings yield above the 10-year Treasury yieldNo P/E on file.
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growthnot known
- –Revenue grew in the newest yearRevenue of the year before is not on file.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- –Earnings per share grew in the newest yearEarnings per share of two years are not on file.
- –Net income higher than five years earlierNet income of five years earlier is not on file.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitabilitynot known
- –Profitable in the newest yearNo net income on file.
- –Profitable in each of the last five yearsFive years of net income are not on file.
- –Operating margin above its peers' medianNo operating margin on file.
- –Return on equity above 15%No return on equity (equity missing or negative).
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health1 of 1
- ✓Short-term assets cover short-term liabilities9.0×Current ratio 8.97 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- –Cash from operations positive in each of the last three yearsThree years of operating cash flow are not on file.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returnsnot known
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- –Share count up no more than 2% in a yearShare counts of two years are not on file.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Events at BlossomHill Therapeutics, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.
Bylaws or fiscal year changed 1 · Results announced 2
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 12, 2026
Acquisitions and funding#
4 private funding rounds before listing
Private share sales · funding history
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
H-1B hiring at BlossomHill Therapeutics, Inc.#
1 labor condition applications certified in fiscal 2026 for 1 positions, at a median wage of $101 K a year.
| Job title | Positions | Median wage offered |
|---|---|---|
| Programming Analyst 2, Clinical TrialsComputer Systems Analysts | 1 | $101 K |
Where: San Diego, CA 1
| Fiscal year | Certified | Positions | Median wage | Filed |
|---|---|---|---|---|
| FY2026 | 1 | 1 | $101 K | 1 |
| FY2025 | 1 | 1 | $432 K | 1 |
Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as BlossomHill Therapeutics, Inc.
Discuss BlossomHill Therapeutics, Inc.#
1 automatic updates and 0 member comments. Sign in to comment and react.
- Results announced on 12 November 2026automatic update · Nov 12, 2026
BlossomHill Therapeutics, Inc. announced results on 12 November 2026 (SEC Form 8-K, item 2.02). For the quarter ended 30 September 2026: a net loss of $24 million.
How BlossomHill Therapeutics, Inc. compares in Biotechnology
- Market cap$458 M · higher than 57% of 726
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| BlossomHill Therapeutics, Inc.🇺🇸 | $458 M | — | — | — |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Regenxbio Inc.$513 M
- Pharmicell Co., Ltd.$514 M
- Pulike Biological Engineering, Inc.$524 M
- Contineum Therapeutics, Inc.$534 M
- Entera Bio Ltd.$543 M
- Arvinas, Inc.$544 M
Sources and freshness
- Market cap:
- Oct 21, 2026
- Balance sheet:
- As of December-2025
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at BlossomHill Therapeutics, Inc.? Verify and update this profile — free
Show BlossomHill Therapeutics, Inc.'s ranking on your website Get the badge
The badge updates itself as the ranking changes.